Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.

Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J.

J Bone Miner Res. 2010 Aug;25(8):1886-94. doi: 10.1002/jbmr.81.

2.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

Wensel TM, Iranikhah MM, Wilborn TW.

Pharmacotherapy. 2011 May;31(5):510-23. doi: 10.1592/phco.31.5.510. Review.

PMID:
21923432
3.

Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.

Moen MD, Keam SJ.

Drugs Aging. 2011 Jan 1;28(1):63-82. doi: 10.2165/11203300-000000000-00000. Review.

PMID:
21174488
4.

Denosumab update.

Lewiecki EM.

Curr Opin Rheumatol. 2009 Jul;21(4):369-73. doi: 10.1097/BOR.0b013e32832ca41c. Review.

PMID:
19424068
5.

[The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].

Varenna M, Gatti D.

Reumatismo. 2010 Jul-Sep;62(3):163-71. Review. Italian.

6.

Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

Dempster DW, Lambing CL, Kostenuik PJ, Grauer A.

Clin Ther. 2012 Mar;34(3):521-36. doi: 10.1016/j.clinthera.2012.02.002. Review.

PMID:
22440513
7.

Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?

Tankó LB.

Curr Opin Investig Drugs. 2007 Oct;8(10):830-5. Review.

PMID:
17907059
8.

Denosumab for treatment of postmenopausal osteoporosis.

Chitre M, Shechter D, Grauer A.

Am J Health Syst Pharm. 2011 Aug 1;68(15):1409-18. doi: 10.2146/ajhp100493. Review.

PMID:
21785030
9.

Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.

Josse R, Khan A, Ngui D, Shapiro M.

Curr Med Res Opin. 2013 Mar;29(3):205-16. doi: 10.1185/03007995.2013.763779. Review. Erratum in: Curr Med Res Opin. 2013 Sep;29(9):1211.

PMID:
23297819
10.

Denosumab: RANKL inhibition in the management of bone loss.

Hamdy NA.

Drugs Today (Barc). 2008 Jan;44(1):7-21. doi: 10.1358/dot.2008.44.1.1178467. Review.

PMID:
18301800
11.

Denosumab for joints and bones.

Lewiecki EM.

Curr Rheumatol Rep. 2009 Jul;11(3):196-201. Review.

PMID:
19604464
12.

Update on denosumab in postmenopausal osteoporosis--recent clinical data.

Muschitz C, Fahrleitner-Pammer A, Huber J, Preisinger E, Kudlacek S, Resch H.

Wien Med Wochenschr. 2012 Sep;162(17-18):374-9. doi: 10.1007/s10354-012-0116-x. Review. Erratum in: Wien Med Wochenschr. 2013 Feb;163(3-4):106.

PMID:
22688622
13.

Denosumab and bisphosphonates: different mechanisms of action and effects.

Baron R, Ferrari S, Russell RG.

Bone. 2011 Apr 1;48(4):677-92. doi: 10.1016/j.bone.2010.11.020. Review.

PMID:
21145999
14.

The effect of antiresorptives on bone quality.

Recker RR, Armas L.

Clin Orthop Relat Res. 2011 Aug;469(8):2207-14. doi: 10.1007/s11999-011-1909-8. Review.

Supplemental Content

Support Center